Patents by Inventor Pavel Majer

Pavel Majer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10954257
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: March 23, 2021
    Assignees: The Johns Hopkins University, Ústav organické chemie a biochemie AV {hacek over (C)}R, v.v.i.
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • Patent number: 10927146
    Abstract: Compounds useful for the treatment of malaria, cancer, Parkinson's disease, diabetes, and bacterial infection.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: February 23, 2021
    Assignee: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I.
    Inventors: Kvido Strisovsky, Pavel Majer, Stanco Stancev, Anezka Ticha
  • Publication number: 20200399298
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA
    Type: Application
    Filed: January 24, 2020
    Publication date: December 24, 2020
    Inventors: BARBARA SLUSHER, RANA RAIS, MARCELA KRECMEROVA, TOMAS TICHY, PAVEL MAJER, ANDREJ JANCARIK
  • Patent number: 10842763
    Abstract: The disclosure provides methods of treating cancer in a subject or preventing a relapse or reducing the incidence of relapse of cancer in a subject in remission, comprising administering to the subject: (a) a therapeutically effective amount of an immunotherapeutic agent, e.g., an immune checkpoint blockade therapy, an adoptive cellular therapy, a marrow-infiltrating lymphocytes, an adenosine A2aR inhibitor, or an antibody; and (b) a compound having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: November 24, 2020
    Assignees: The Johns Hopkins University, Ústav organické chemie a biochemie AV {hacek over (C)}r, v.v.i.
    Inventors: Barbara Slusher, Jonathan Powell, Lukas Tenora, Pavel Majer, Andrei Jancarik, Robert Leone, Judson Englert
  • Patent number: 10738066
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: August 11, 2020
    Assignees: The Johns Hopkins University, Ústav organické chemie a biochemie AV {hacek over (C)}R, v.v.i.
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • Publication number: 20200230111
    Abstract: Prodrugs of glutamine analogs, such as prodrugs of acivicin, are disclosed.
    Type: Application
    Filed: February 1, 2018
    Publication date: July 23, 2020
    Inventors: Barbara Slusher, Pavel Majer, Lukas Tenora, Katerina Novotna, Peter Michael Hudlicky
  • Patent number: 10718772
    Abstract: A method for detection of active form of analytes in a sample and/or for determination of ability of tested substances to bind to the active site of these analytes has the following steps: a) analyte or group of analytes from the sample is immobilized on the surface of a solid carrier; b) analyte or group of analytes is incubated with a detection probe; c) then the solid carrier is washed to remove unbound detection probe; and subsequently, the amount of bound detection probe is determined.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: July 21, 2020
    Assignee: USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR, V.V.I.
    Inventors: Vaclav Navratil, Pavel Sacha, Jiri Schimer, Jan Konvalinka, Pavel Majer
  • Publication number: 20200095278
    Abstract: Compounds useful for the treatment of malaria, cancer, Parkinson's disease, diabetes, and bacterial infection.
    Type: Application
    Filed: June 12, 2018
    Publication date: March 26, 2020
    Applicant: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I.
    Inventors: Kvido STRISOVSKY, Pavel MAJER, Stanco STANCEV, Anezka TICHA
  • Patent number: 10544176
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: January 28, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Barbara Slusher, Rana Rais, Marcela Krecmerova, Tomas Tichy, Pavel Majer, Andrej Jancarik
  • Publication number: 20190352255
    Abstract: Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
    Type: Application
    Filed: November 20, 2017
    Publication date: November 21, 2019
    Inventors: Barbara Slusher, Rana Rais, Jan Vavra, Tomas Tichy, Pavel Majer, Andrej Jancarik, Lukas Tenora
  • Publication number: 20190315783
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Application
    Filed: June 27, 2019
    Publication date: October 17, 2019
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • Publication number: 20190315784
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Application
    Filed: June 27, 2019
    Publication date: October 17, 2019
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • Patent number: 10336778
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: July 2, 2019
    Assignees: The Johns Hopkins University, Ústav organické chemie a biochemie AV {hacek over (C)}R, v.v.i.
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • Patent number: 10302632
    Abstract: A macromolecular water-soluble conjugates based on synthetic copolymers to which at least one affinity tag, at least one imaging probe and at least one targeting ligand are bound via covalent bonds. The macromolecular conjugate may be used in identification, visualization, quantification or isolation of proteins and/or cells.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: May 28, 2019
    Assignees: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I., USTAV MAKROMOLEKULARNI CHEMIE AV CR, V.V.I., UNIVERZITA KARLOVA V PRAZE, PRIRODOVEDECKA FAKULTA
    Inventors: Pavel Sacha, Jan Konvalinka, Jiri Schimer, Tomas Knedlik, Vaclav Navratil, Jan Tykvart, Frantisek Sedlak, Pavel Majer, Petr Cigler, Vladimir Subr, Karel Ulbrich, Jiri Strohalm
  • Publication number: 20190033300
    Abstract: A macromolecular water-soluble conjugates based on synthetic copolymers to which at least one affinity tag, at least one imaging probe and at least one targeting ligand are bound via covalent bonds. The macromolecular conjugate may be used in identification, visualization, quantification or isolation of proteins and/or cells.
    Type: Application
    Filed: September 12, 2018
    Publication date: January 31, 2019
    Applicants: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I., USTAV MAKROMOLEKULARNI CHEMIE AV CR, V.V.I., UNIVERZITA KARLOVA V PRAZE, PRIRODOVEDECKA FAKULTA
    Inventors: PAVEL SACHA, JAN KONVALINKA, JIRI SCHIMER, TOMAS KNEDLIK, VACLAV NAVRATIL, JAN TYKVART, FRANTISEK SEDLAK, PAVEL MAJER, PETR CIGLER, VLADIMIR SUBR, KAREL ULBRICH, JIRI STROHALM
  • Publication number: 20180244705
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Application
    Filed: May 1, 2018
    Publication date: August 30, 2018
    Inventors: BARBARA SLUSHER, RANA RAIS, MARCELA KRECMEROVA, TOMAS TICHY, PAVEL MAJER, ANDREJ JANCARIK
  • Publication number: 20180222930
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Application
    Filed: January 31, 2018
    Publication date: August 9, 2018
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • Patent number: 9988407
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: June 5, 2018
    Assignees: THE JOHNS HOPKINS UNIVERSITY, INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Marcela Krecmerova, Tomas Tichy, Pavel Majer, Andrej Jancarik
  • Publication number: 20180052152
    Abstract: Macromolecular water-soluble conjugates based on synthetic copolymers to which at least one affinity tag, at least one imaging probe, and at least one targeting ligand are bound via covalent bonds. The macromolecular conjugate may be used in identification, visualization, quantification or isolation of proteins and/or cells. The targeting ligand may be attached to the synthetic copolymer via a flexible linker.
    Type: Application
    Filed: January 13, 2016
    Publication date: February 22, 2018
    Applicants: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I., USTAV MAKROMOLEKULARNI CHEMIE AV CR, V.V.I., UNIVERZITA KARLOVA V PRAZE, PRIRODOVEDECKA FAKULTA
    Inventors: Pavel Sacha, Jan KONVALINKA, Jiri SCHIMER, Tomas KNEDLIK, Vaclav NAVRATIL, Jan TYKVART, Frantisek SEDLAK, Pavel MAJER, Petr CIGLER, Vladimir SUBR, Karel ULBRICH, Jiri STROHALM
  • Publication number: 20170226141
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Application
    Filed: August 6, 2015
    Publication date: August 10, 2017
    Applicants: The Johns Hopkins University, Institute of Organic Chemistry and Biochemistry as Cr v.v.i.
    Inventors: Barbara SLUSHER, Rana RAIS, Marcela KRECMEROVA, Tomas TICHY, Pavel MAJER, Andrej JANCARIK